Torrent Pharma recalls Semalix injection batches after Dr Reddy's flags API quality issue
Synopsis
Torrent Pharmaceuticals has pulled select batches of its Semalix injection pens after manufacturing partner Dr Reddy's found the active ingredient out of specification — a rare public quality flag in India's fast-growing semaglutide market. Both companies say there is no patient risk, but commercial supplies from Dr Reddy's remain on hold pending a root-cause investigation.
Key Takeaways
Torrent Pharmaceuticals announced a voluntary recall of Semalix Injection 2 mg and 4 mg batches on 9 July 2025 .
The trigger: manufacturing partner Dr Reddy's Laboratories found certain batches out of specification due to an API quality issue .
Both companies state the issue poses no risk to patient safety .
Dr Reddy's has suspended commercial semaglutide supplies until the root cause is identified and corrected.
Unaffected products include Semalix tablets (3 mg, 7 mg, 14 mg) , Sembolic tablets , Semalix Injection 8 mg (by MSN Laboratories), and Sembolic reusable injection (by Zydus Lifesciences).
Torrent Pharma shares closed 0.6% higher at ₹4,896.65 on the BSE on the day of the announcement.
Torrent Pharmaceuticals on Thursday, 9 July announced a voluntary recall of select batches of its Semalix injection disposable pens as a precautionary measure, after manufacturing partner Dr Reddy's Laboratories identified a quality issue with the active pharmaceutical ingredient (API) used in the product. The recall covers Semalix Injection 2 mg and 4 mg strengths manufactured by Dr Reddy's and does not extend to other semaglutide products in Torrent's portfolio.
What Triggered the Recall
Earlier on Thursday, Dr Reddy's Laboratories informed stock exchanges that commercial supplies of semaglutide would be put on hold after certain batches were found to be out of specification due to an issue with the API. The Hyderabad-based drugmaker said it is investigating the root cause and implementing corrective measures. It added that commercial supplies will remain suspended until the matter is resolved.
Dr Reddy's also clarified that the issue does not affect the product's existing global regulatory filings and poses no risk to patient safety.
Torrent's Assurance on Patient Safety
Torrent emphasised that the recall is purely precautionary and that patients currently on treatment face no identified risk. The company reiterated that patient safety remains its highest priority and has advised patients and caregivers with queries about the affected batches to contact the company directly for clarification.
Products Not Affected
Torrent confirmed that several other products in its semaglutide range remain unaffected. These include Semalix tablets in 3 mg, 7 mg, and 14 mg strengths, Sembolic tablets in the same strengths manufactured by Torrent, Semalix Injection 8 mg manufactured by MSN Laboratories, and the Sembolic reusable injection manufactured by Zydus Lifesciences.
Market Reaction
Despite the recall announcement, shares of Torrent Pharmaceuticals closed the session at ₹4,896.65 on the BSE, gaining ₹29.20, or 0.6%, suggesting markets viewed the precautionary action as limited in scope. The recall underscores the regulatory and supply-chain complexities inherent in India's rapidly expanding semaglutide market, where multiple manufacturers are racing to meet surging demand for the weight-management and diabetes drug.
The development will be closely watched by healthcare professionals and patients as Dr Reddy's works to resolve the API specification issue and resume commercial supplies.
Point of View
But the episode exposes a structural vulnerability in India's semaglutide supply chain: multiple brands rely on a narrow set of API suppliers, meaning a single specification failure can ripple across the market. Dr Reddy's decision to proactively notify stock exchanges is commendable for transparency, yet the absence of detail on which API lot is implicated leaves prescribers and pharmacists with limited information to act on. As India's appetite for GLP-1 drugs accelerates — driven by rising obesity and diabetes diagnoses — regulators and manufacturers need more robust API quality checkpoints upstream, not just post-production batch testing. The market's muted reaction suggests investors read this as contained; the real test is how quickly Dr Reddy's can restore supply without a repeat.
NationPress
9 Jul 2026
Frequently Asked Questions
Which Semalix batches have been recalled by Torrent Pharma?
Torrent Pharmaceuticals has recalled select batches of Semalix Injection 2 mg and 4 mg disposable pens. These specific batches were manufactured by Dr Reddy's Laboratories and were found to have an active pharmaceutical ingredient (API) quality issue requiring technical evaluation.
Is there any risk to patients using the recalled Semalix injections?
Both Torrent Pharmaceuticals and Dr Reddy's Laboratories have stated that the recall poses no identified risk to patient safety. The action is described as purely precautionary, pending a technical investigation into the API specification issue.
Why did Dr Reddy's Laboratories halt semaglutide supplies?
Dr Reddy's informed stock exchanges that certain semaglutide batches were found out of specification due to an issue with the active pharmaceutical ingredient (API). The company has suspended commercial supplies until the root cause is identified and corrective measures are implemented.
Which semaglutide products from Torrent are not affected by the recall?
The recall is limited to Semalix Injection 2 mg and 4 mg. Unaffected products include Semalix tablets (3 mg, 7 mg, 14 mg), Sembolic tablets in the same strengths, Semalix Injection 8 mg manufactured by MSN Laboratories, and the Sembolic reusable injection manufactured by Zydus Lifesciences.
What should patients do if they have the recalled Semalix injection batches?
Torrent Pharmaceuticals has advised patients and caregivers with queries about the affected batches to contact the company directly for clarification and guidance. Patients currently on treatment are advised not to discontinue medication without consulting their doctor.
